http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
-
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
-
Amgen (AMGN) Cytokinetics (CYTK) and Servier Report Continuation of GALACTIC-HF Following Planned Interim Analysis
-
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
-
Amgen, Cytokinetics and Servier Announce Continuation of GALACTIC-HF Following Planned Interim Analysis
-
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
-
Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
-
Cytokinetics (CYTK) Reports Publication of Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Heart Failure
-
Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
-
Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
-
Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
-
Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
-
Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
-
Cytokinetics (CYTK) Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
-
Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
-
Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND
-
Cytokinetics to Participate in the Piper Jaffray Healthcare Conference
-
Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
-
Amgen (AMGN), Cytokinetics (CYTK) Announces New Results From COSMIC-HF Presented at AHA
-
New Results From COSMIC-HF Presented At AHA 2019 Show Treatment Of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral Or Improved Measures Of Diastolic Function
-
New Results From COSMIC-HF Presented at AHA 2019 Show Treatment of Heart Failure Patients With Omecamtiv Mecarbil Was Associated With Neutral or Improved Measures of Diastolic Function
-
Cytokinetics Reports Third Quarter 2019 Financial Results
-
Cytokinetics to Announce Third Quarter Results on October 31, 2019
-
Cytokinetics (CYTK) Announces Presentation of Additional Analyses From FORTITUDE-ALS at NEALS
-
Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting
-
Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference
-
Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting
-
Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals
-
Cytokinetics (CYTK) Highlights Data From Phase 1 Study of CK-3773274 at HFSA 2019 Meetings
-
Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting
-
Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting
-
Cytokinetics to Present at September Investor Conferences
-
Cytokinetics Reports Second Quarter 2019 Financial Results
-
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
-
Cytokinetics to Announce Second Quarter Results on August 8, 2019
-
Cytokinetics (CYTK) Reports Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
-
Cytokinetics Announces Publication of Preclinical Data Demonstrating Fast Skeletal Muscle Troponin Activator Improves Muscle Energetics
-
Cytokinetics (CYTK) Granted European Orphan Designation for Reldesemtiv for the Treatment of SMA
-
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
-
Cytokinetics (CYTK) Announces Preclinical Data Relating to CK-3773274 to be Presented at BCVS
-
Cytokinetics Announces Preclinical Data Relating to CK-3773274 to be Presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions
-
Cytokinetics (CYTK) Reports Complete Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil
-
Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
-
Cytokinetics (CYTK) Announces Preclinical Data For Reldesemtiv Presented at SMA Conference
-
Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
-
Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference
-
Cytokinetics to Present at the JMP Securities Life Sciences Conference
-
Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS
-
Cytokinetics Reports First Quarter 2019 Financial Results
-
Cytokinetics to Hold Annual Meeting of Stockholders

